Rapid detection of mutation in isocitrate dehydrogenase 1 and 2 genes using mass spectrometry

Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting

(2018) Anna Tietze et al.   JOURNAL OF NEUROSURGERY

The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis

(2017) Maarten M J Wijnenga et al.   NEURO-ONCOLOGY

Metabolic Profiling of IDH Mutation and Malignant Progression in Infiltrating Glioma

(2017) Llewellyn E. Jalbert et al.   Scientific Reports

Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion

(2016) Tomohiro Kawaguchi et al.   JOURNAL OF NEURO-ONCOLOGY

An immuno-wall microdevice exhibits rapid and sensitive detection of IDH1-R132H mutation specific to grade II and III gliomas

(2016) Akane Yamamichi et al.   SCIENCE AND TECHNOLOGY OF ADVANCED MATERIALS

Noninvasive Quantification of 2-Hydroxyglutarate in Human Gliomas with IDH1 and IDH2 Mutations

(2015) U. E. Emir et al.   CANCER RESEARCH

Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma

(2015) Macarena I. de la Fuente et al.   NEURO-ONCOLOGY

Rapid and sensitive intraoperative detection of mutations in the isocitrate dehydrogenase 1 and 2 genes during surgery for glioma

(2014) Masayuki Kanamori et al.   JOURNAL OF NEUROSURGERY

Intraoperative mass spectrometry mapping of an onco-metabolite to guide brain tumor surgery

(2014) S. Santagata et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection

(2013) Jason Beiko et al.   NEURO-ONCOLOGY

The Potential for Isocitrate Dehydrogenase Mutations to Produce 2-Hydroxyglutarate Depends on Allele Specificity and Subcellular Compartmentalization

(2012) Patrick S. Ward et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas

(2012) Changho Choi et al.   NATURE MEDICINE

IDH1/2 gene status defines the prognosis and molecular profiles in patients with grade III gliomas

(2011) Ichiyo Shibahara et al.   International Journal of Clinical Oncology

Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy

(2011) Whitney B. Pope et al.   JOURNAL OF NEURO-ONCOLOGY

Application of Mutant IDH1 Antibody to Differentiate Diffuse Glioma From Nonneoplastic Central Nervous System Lesions and Therapy-induced Changes

(2010) David Capper et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate

(2010) Patrick S. Ward et al.   CANCER CELL

Detection of IDH1 and IDH2 Mutations by Fluorescence Melting Curve Analysis as a Diagnostic Tool for Brain Biopsies

(2010) Craig Horbinski et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Analysis ofIDH1andIDH2mutations in Japanese glioma patients

(2009) Yukihiko Sonoda et al.   CANCER SCIENCE

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

(2009) Lenny Dang et al.   NATURE

Predictive factors for overall and progression-free survival, and dissemination in oligodendroglial tumors

(2008) Masayuki Kanamori et al.   JOURNAL OF NEURO-ONCOLOGY

An Integrated Genomic Analysis of Human Glioblastoma Multiforme

(2008) D. W. Parsons et al.   SCIENCE